EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study

Suha Abushamma iD, Ted Walker, Kevin Garza, Ling Chen, Darren Nix, Chien-Huan Chen

Crohn's & Colitis 360 · 01.07.2023 · 5 (3)

DOI: 10.1093/crocol/otad022 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Crohn's & Colitis 360, online erschienen am 03.05.2023. Verfasst von Suha Abushamma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Infliximab is typically given over an infusion time of 2 hours, leading to a significant burden in inflammatory bowel disease (IBD) patients. We aimed to determine the safety and cost-effectiveness of an accelerated infliximab infusion of 1 hour, compared with the standard 2-hour infusion.

Methods

Open-label randomized trial where IBD patients receiving maintenance infliximab infusions were randomly assigned to 1- and 2-hour infusion groups, corresponding to study and control groups, respectively. The primary outcome was the rate of infusion reactions. Secondary outcomes were assessment of the effect of premedications and immunomodulators on the rate of infusion reactions, and cost-effectiveness analysis. The cost-effectiveness analysis was based on direct nursing costs for the infusion time, indirect infusion center costs, and cost of productivity loss for patients. This trial is registered with ClinicalTrials.gov, NCT05340764.

Results

From November 2020 to November 2021, 96 patients were randomly assigned: 51 (53%) to the 1-hour infusion group and 45 (47%) to the 2-hour infusion group. Over a median time of 1 year, 309 infusions were administered in the control group, and 376 in the study group. Fifty-seven (18%) infusions in the control group and 45 (12%) infusions in the study group experienced an infusion reaction. The only infusion reaction was asymptomatic hypotension not requiring infusion discontinuation. No other infusion reactions (mild or moderate/severe) were seen. Diphenhydramine was associated with an increased rate of infusion reactions (OR 2.04 [95% CI 1.18–3.52], P = .01). The average costs were estimated to reduce by 37% in the accelerated infusion group.

Conclusions

Accelerated 1-hour infusions are non-inferior in safety and superior in cost-effectiveness compared with standard 2-hour infusions in IBD patients receiving maintenance infliximab infusions. Trial Identification Number Registered with ClinicalTrials.gov, NCT05340764.

Schlagwörter

Stichwörter der Autor:innen

accelerated infusioninflammatory bowel diseaseinfliximab

Autor:innen und Institutionen

  • Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
  • Division of General Medicine, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Biostatistics, Washington University School of Medicine, Saint Louis, Missouri, USA.

ORCID-Profile: Suha Abushamma

Zitieren

APA

Abushamma, S., Walker, T., Garza, K., Chen, L., Nix, D., & Chen, C. H. (2023). Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study. Crohn's & Colitis 360, 5(3). https://doi.org/10.1093/crocol/otad022

Vancouver

Abushamma S, Walker T, Garza K, Chen L, Nix D, Chen CH. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study. Crohn's & Colitis 360. 2023;5(3). doi:10.1093/crocol/otad022

BibTeX
@article{Abushamma2023,
  author = {Abushamma, Suha and Walker, Ted and Garza, Kevin and Chen, Ling and Nix, Darren and Chen, Chien-Huan},
  title = {Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study},
  journal = {Crohn's & Colitis 360},
  year = {2023},
  volume = {5},
  number = {3},
  doi = {10.1093/crocol/otad022}
}
Kostenlos starten →